AIOSYN
29.2.2024 13:27:30 CET | Business Wire | Press release
Aiosyn, a pioneering medical software company specializing in AI-powered pathology solutions for cancer and kidney disease, announced the introduction of its NephroPath platform. By partnering with Aiosyn, CROs, biopharma, and researchers can accelerate the development of Chronic Kidney Disease (CKD) therapies using new and quantitative insights offered through Nephropath’s Kidney Image Analysis Services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240228760007/en/
Figure 1. Illustration of the NephroPath platform’s capabilities in performing automated quantification and multi-class prediction on an entire rat kidney cortex. Notable classes: normal tubuli (orange), atrophic/dilated tubuli (green/red), glomeruli (pink), abnormal/sclerotic glomeruli (dark blue), arteries (light blue), interstitium (not colored). (Photo: Business Wire)
The NephroPath platform provides computational pathology algorithms for a detailed evaluation of histological biomarkers in kidney biopsies, including segmentation of main tissue classes, quantification of interstitial fibrosis, precise localization and quantification of glomeruli, and more. These AI-powered analyses effectively overcome the constraints of current semi-quantitative scoring systems, which are often based on subregions of the kidney and are subject to observer variability.
NephroPath’s AI-based quantification provides reproducible, consistent, fast, and more detailed scoring of renal pathology (imaging) biomarkers in preclinical and clinical specimens* compared to human reading. This can accelerate preclinical and clinical development projects. The algorithms will also be instrumental in new CKD biomarker discovery projects.
Through Nephropath’s Kidney Image Analysis Services, Aiosyn offers whole kidney quantification and custom kidney analyses. Aiosyn’s data-rich analysis derived from slide data provides per-slide tissue quantifications and detailed dataset characterization. Findings are delivered in a comprehensive image analysis report, including biomarker scores and visual results.
“Using Aiosyn's NephroPath platform we provide researchers with a new and powerful technique to complement the CKD drug development toolbox,” said Patrick de Boer, CEO of Aiosyn.
CKD is forecasted to grow to the fifth predominant cause of mortality by 2040 (1), and with over 90+ new CKD therapies in development, there is a need for advanced tools that can accelerate drug development and enhance diagnostic accuracy.
In a recent preclinical study, conducted in collaboration with a leading preclinical research organization (CRO), the NephroPath platform demonstrated its effectiveness in segmenting kidney tissue classes (Figure 1) and quantifying glomerulosclerosis and tubular damage on whole rat kidneys. A positive correlation was observed between the glomerulosclerosis and tubular scores and kidney damage across all groups (the study abstract will be presented at the upcoming CKD Summit in Boston from March 19-21).
To learn more about the NephroPath platform and to explore potential collaboration, request a demo with our team.
About Aiosyn
Aiosyn is a Dutch company that develops precision pathology software for cancer and kidney disease. Aiosyn’s solutions are integrated into standard pathology workflows. The Aiosyn team has been built upon more than 20 years of research experience in the field of pathology and is rooted in the pathology practice.
*For scientific validity only. The NephroPath platform is for Research Use Only and should not be used for diagnostic procedures.
Sources
- Foreman, K. J., Marquez, N., Dolgert, A., Fukutaki, K., Fullman, N., McGaughey, M., … & Murray, C. J. (2018). Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. The Lancet, 392(10159), 2052-2090.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228760007/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
mimik Operationalizes Agentic AI on the AMD Ryzen™ AI Embedded X100 Series23.7.2026 20:30:00 CEST | Press release
mimik today announced mimOE™ Embedded Edition, a package of its Agentix Operating Engine and a set of purpose-built tools for the AMD Ryzen™ AI Embedded X100 Series processor, the newest processor in a family designed for physical AI, autonomous systems, and industrial automation. Available to download today, mimOE Embedded Edition gives OEMs, tier-1 suppliers, system integrators, and agent developers the path to operationalize Agentix-Native systems (aka Agentic AI), in which autonomous agents can reason, coordinate, and act directly on devices, from PoC to scaled operations with certainty. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260723555565/en/ Agentic AI operations are both CPU and GPU bound. Enterprises can now scale with certainty. Generative AI has centered on the GPU. Agentix-Native systems must spread the work. In a real multi-agent workflow traced by mimik, more than 80 percent of operations were CPU work: d
U.S. Federal Court Permanently Bans 19 Online Sellers of Fake Urolithin A Supplements and Awards $5.3 Million in Damages to Timeline23.7.2026 16:27:00 CEST | Press release
Default judgment follows Timeline’s independent laboratory testing showing products sold under 19 online brands contained no detectable Urolithin A, or far less than advertised Timeline (Amazentis SA), the Swiss life-sciences company that pioneered the postbiotic ingredient Urolithin A and its branded form Mitopure®, together with its U.S. subsidiary Timeline Longevity, Inc., announced today that the U.S. District Court for the District of Massachusetts has granted the companies’ motion for default judgments and permanent injunctions against 19 online sellers found to have marketed and sold nutritional supplements falsely advertised as containing Urolithin A. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722951066/en/ Timeline longevity supplement powered by Mitopure; proprietary, highly pure Urolithin A. The order, entered July 15, 2026 by Judge Myong J. Joun in Amazentis SA et al. v. The Partnerships and Unincorporated
TestMu AI Introduces the Source-to-Verdict Loop in Kane CLI, Carrying Every Requirement to a Ship Decision With Portable Proof23.7.2026 15:45:00 CEST | Press release
Kane CLI now takes a requirement all the way to a ship-or-hold verdict, designing the tests, running them in a real browser, and emitting an open .evidence proof pack that teammates, AI agents, and auditors can all verify, with no server or dashboard required TestMu AI (formerly LambdaTest), the world's first Agentic AI-powered Quality Engineering platform, introduced a source-to-verdict loop in Kane CLI, its natural-language testing tool. Building on Kane CLI's evolution from a browser automation tool, the loop carries a product requirement to a ship decision, writing the tests, running them in the local browser, collecting the proof, measuring coverage from what actually happened, and returning a verdict. As AI agents write, run, and fix tests, a green checkmark is no longer enough: a step that checks nothing passes, a test written against a spec that changed weeks ago passes, and an agent that says “done” without the click ever landing passes. Empty green and earned green are the sa
Norway’s health system adopts Wolters Kluwer UpToDate Enterprise Edition23.7.2026 15:30:00 CEST | Press release
Enterprise Clinical Decision Support solution available to 30,000 clinicians in more than 50 Norwegian hospitals Wolters Kluwer Health announced that Norway’s health system has renewed its adoption of UpToDate Enterprise Edition, a market-leading Clinical Decision Support (CDS) solution, for its nationwide health system which includes over 50 public hospitals and 11,000 beds in over 20 trusts. This extends a 15 year partnership with Helsebiblioteket, now part of the Norwegian Institute of Public Health (NIPH). Helping clinicians on a national scale Kjell Tjensvoll, Team Leader for Helsebiblioteket said, ‘‘Providing frontline teams with easy access to the latest medical knowledge is vital in reducing unwarranted variation and improving patient care on a national scale. UpToDate Enterprise Edition enables this, and we are delighted to strengthen our relationship with Wolters Kluwer and provide continued support for clinicians across the country.’’ UpToDate Enterprise Edition was selected
Boyd Watterson Global Names John Creswell Global Chief Client Officer to Accelerate Global Growth and Client Engagement23.7.2026 15:00:00 CEST | Press release
Veteran investment management executive will lead global sales, client engagement and marketing as Boyd Watterson Global continues expanding its global alternatives platform across real estate, infrastructure, and debt strategies. Boyd Watterson Global today announced the appointment of John Creswell as Global Chief Client Officer, a newly created senior leadership role that reflects the firm's continued investment in growth and its evolution into a leading global alternatives investment platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722823117/en/ John Creswell has joined Boyd Watterson Global as Global Chief Client Officer, a newly created role overseeing global sales, client engagement and marketing across the U.S., Europe and APAC. In this role, Creswell will oversee global sales, client engagement and marketing efforts across the United States, Europe and APAC, helping investors access the firm's capabilitie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom